aldose reductase inhibitor


aldose reductase inhibitor

Any of a family of compounds (e.g., epalrestat, ponalrestat, sorbinil, tolrestat) that block aldose reductase, which catalyses the reduction of glucose to sorbitol; accumulation of polyols through the autosomal recessive pathway is believed to lead to microvascular and neurologic complications of diabetes. Increased intracellular glucose leads to increased sorbitol, which competitively inhibits glomerular and neural synthesis of myo-inositol; the decrease in myo-inositol synthesis depresses phosphoinositide metabolism and reduces Na+K+-ATPase activity. ARIs do not prevent the complications of type-1 diabetes.

aldose reductase inhibitor

Clinical therapeutics Any of a family of compounds–eg, epalrestat, ponalrestat, sorbinil, tolrestat, which block aldose reductase; ↑ intracellular glucose leads to ↑ sorbitol, which competitively inhibits glomerular and neural synthesis of myo-inositol; the ↓ in myo-inositol synthesis depresses phosphoinositide metabolism, and ↓ in Na+K+-ATPase activity; ARIs do not prevent the complications of type 1 DM See Aldose reductase.